Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HanchorBio's revenue for the
three
months ended in Mar. 2026 was NT$0.0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was NT$312.2 Mil.
HanchorBio's Revenue per Share for the
three
months ended in Mar. 2026 was NT$0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was NT$2.52.
During the past 3 years, the average Revenue per Share Growth Rate was 496.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 4 years, HanchorBio's highest 3-Year average Revenue per Share Growth Rate was 496.40% per year. The lowest was 496.40% per year. And the median was 496.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
HanchorBio Revenue Related Terms
HanchorBio Revenue Historical Data
* Premium members only.
The historical data trend for HanchorBio's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, HanchorBio's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HanchorBio Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HanchorBio's Revenue distribution charts can be found below:
* The bar in red indicates where HanchorBio's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$312.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HanchorBio (TPE:7827) has a Revenue of NT$312.2 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on HanchorBio and its competitors.
Is HanchorBio's Revenue too high?
HanchorBio's current Revenue is NT$312.2 Mil. Overall, HanchorBio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does HanchorBio's Revenue compare to VRTX and REGN?
HanchorBio's Revenue of NT$312.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on HanchorBio and its competitors. HanchorBio's current Revenue is NT$312.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HanchorBio stock overvalued right now?
HanchorBio (TPE:7827) has a current Revenue of NT$312.2 Mil. The current Revenue is NT$312.2 Mil. HanchorBio's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For HanchorBio (TPE:7827), the current Revenue is NT$312.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HanchorBio Inc through its subsidiaries, is conducting research and development of new anti-cancer drugs, utilizing an Fc-based biopharmaceutical platform technology to reactivate the immune system in the fight against disease. The core technology of HanchorBio is the FBDB (Fc-Based Designer Biologics) platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutics. This platform utilizes the antibody Fc region as a backbone, onto which various engineered anti-cancer molecules are constructed through protein engineering. Combined with AI-assisted drug design capabilities, this technology is dedicated to overcoming key challenges in tumor immunotherapy.
9GF Score
Get the complete analysis for TPE:7827
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7827 has been successfully added to your 
